PHI with Epidermolysis bullosa acquisita
How does this condition affect your private health insurance?
Epidermolysis bullosa acquisita (EBA) is a rare, chronic autoimmune blistering disease primarily affecting the skin and mucous membranes. It arises from autoantibodies targeting type VII collagen, crucial for anchoring the epidermis to the dermis. This leads to extreme skin fragility, recurrent blisters, erosions, and pronounced scarring, particularly in areas of friction. Healing often results in atrophic scars and milia. EBA can also involve the oral cavity, eyes, and esophagus, causing significant pain, dysphagia, and potential visual impairment. Diagnosis relies on specific immunofluorescence findings, and management typically involves immunosuppressive therapies to control symptoms.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months for diagnosis and initial stabilization of symptoms.
Duration of Illness (Lifetime)
Chronic, lifelong disease with periods of flares and remission, often requiring continuous management.
Cost of Treatment (Initial)
High, potentially several thousand dollars for diagnostics and initial immunosuppressive medications.
Cost of Treatment (Lifetime)
Very high, potentially tens to hundreds of thousands of dollars over a lifetime due to ongoing medication, specialized wound care, and potential biologics.
Mortality Rate
Low to moderate, primarily due to severe complications like widespread infections or extensive internal organ involvement, rather than the disease being directly fatal.
Risk of Secondary Damages
High, including significant scarring, milia, nail dystrophy, ocular complications (e.g., conjunctivitis, synechiae), esophageal strictures, dental issues, chronic pain, and considerable psychological distress.
Probability of Full Recovery
Low; while sustained remission can be achieved with treatment, complete recovery without any residual consequences or risk of relapse is uncommon.
Underlying Disease Risk
Low to moderate; a subset of patients may have an association with inflammatory bowel disease (especially Crohn's disease) or other autoimmune conditions.